Corium International, Inc. (NASDAQ:CORI) major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $11.05, for a total value of $1,657,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Wednesday, October 4th, Healthcare Master Fun Broadfin sold 218,100 shares of Corium International stock. The shares were sold at an average price of $11.01, for a total value of $2,401,281.00.

Corium International, Inc. (NASDAQ CORI) traded up $0.71 during trading hours on Friday, hitting $11.21. The stock had a trading volume of 102,290 shares, compared to its average volume of 108,883.

Corium International (NASDAQ:CORI) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). The company had revenue of $8.11 million for the quarter, compared to the consensus estimate of $8.71 million. Corium International had a negative net margin of 145.60% and a negative return on equity of 673.17%. sell-side analysts predict that Corium International, Inc. will post -1.74 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Corium International, Inc. (CORI) Major Shareholder Sells $1,657,500.00 in Stock” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/03/corium-international-inc-cori-major-shareholder-sells-1657500-00-in-stock.html.

A number of hedge funds have recently modified their holdings of CORI. Bank of New York Mellon Corp grew its holdings in Corium International by 118.1% in the 1st quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 13,683 shares in the last quarter. New York State Common Retirement Fund bought a new position in Corium International in the 2nd quarter worth approximately $158,000. California State Teachers Retirement System bought a new position in Corium International in the 2nd quarter worth approximately $263,000. Teachers Advisors LLC bought a new position in Corium International in the 2nd quarter worth approximately $272,000. Finally, TIAA CREF Investment Management LLC bought a new position in Corium International in the 2nd quarter worth approximately $411,000. 90.14% of the stock is owned by institutional investors and hedge funds.

Several analysts recently weighed in on the company. Zacks Investment Research raised Corium International from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Tuesday, October 3rd. Cantor Fitzgerald reissued a “buy” rating and issued a $12.00 price objective on shares of Corium International in a report on Wednesday, September 27th. HC Wainwright assumed coverage on Corium International in a report on Tuesday, September 26th. They issued a “buy” rating and a $15.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $13.00 price objective on shares of Corium International in a report on Sunday, September 17th. Finally, Jefferies Group LLC set a $10.00 target price on Corium International and gave the company a “buy” rating in a report on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. Corium International has an average rating of “Buy” and a consensus price target of $13.00.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.